Difference between revisions of "CureMILS"
From Bioblast
Tindle Lisa (talk | contribs) (Created page with " {{Template:OROBOROS header page name}} <big><big>'''"A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome (MILS...") Â |
Tindle Lisa (talk | contribs) Â |
||
(4 intermediate revisions by the same user not shown) | |||
Line 11: | Line 11: | ||
::::*Â EJP RD JTC 2020: "PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASESâ - Project EJPRD20-010 | ::::*Â EJP RD JTC 2020: "PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASESâ - Project EJPRD20-010 | ||
::::* '''Duration''': 36 months  | ::::* '''Duration''': 36 months  | ||
::::* '''Start''':Â Â | ::::* '''Start''':Â 2021-06-01 | ||
 | |||
== About CureMILS == | == About CureMILS == | ||
Line 28: | Line 28: | ||
== Coordinator== | == Coordinator== | ||
::::*Â [[Prigione Alessandro| Prof. Dr. Alessandro Prigione]] - [https://www.uniklinik-duesseldorf.de/ | ::::*Â [[Prigione Alessandro| Prof. Dr. Alessandro Prigione]] - [https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/klinik-fuer-allgemeine-paediatrie-neonatologie-und-kinderkardiologie/forschung/stammzell-metabolismus Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University], DE | ||
[[Image:Hhu logo.pngââ|110px|Heinrich Heine University]] | [[Image:Hhu logo.pngââ|110px|Heinrich Heine University]] | ||
== Network == | == Network == | ||
Line 35: | Line 35: | ||
::::* Prof. Dr. Frank Edenhofer - [https://www.uibk.ac.at/molbiol/index.html.en Institute for Molecular Biology, University of Innsbruck], AT | ::::* Prof. Dr. Frank Edenhofer - [https://www.uibk.ac.at/molbiol/index.html.en Institute for Molecular Biology, University of Innsbruck], AT | ||
::::* [[Koopman Werner JH| Dr. Werner Koopman]] - [https://www.radboudumc.nl/en/research/departments/biochemistry Radboud University Medical Center, Biochemistry], NL | ::::* [[Koopman Werner JH| Dr. Werner Koopman]] - [https://www.radboudumc.nl/en/research/departments/biochemistry Radboud University Medical Center, Biochemistry], NL | ||
::::* Dr. Anu Suomalainen - [https://www.helsinki.fi/en/researchgroups/stem-cells-and-metabolism-research-program University of Helsinki, Research Program of Stem Cells and Metabolism], FI | ::::* [[Suomalainen Anu|Dr. Anu Suomalainen]] - [https://www.helsinki.fi/en/researchgroups/stem-cells-and-metabolism-research-program University of Helsinki, Research Program of Stem Cells and Metabolism], FI | ||
::::* Dr. PaweĆ Lisowski - [http://www.ighz.edu.pl/en/ Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Department of Molecular Biology], PL | ::::* Dr. PaweĆ Lisowski - [http://www.ighz.edu.pl/en/ Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Department of Molecular Biology], PL | ||
::::* Dr. Emanuela Bottani - [https://www.ddsp.univr.it/?ent=home&page=dipartimento&lang=en Verona University, Department of Diagnostics and Public Health], IT | ::::* Dr. Emanuela Bottani - [https://www.ddsp.univr.it/?ent=home&page=dipartimento&lang=en Verona University, Department of Diagnostics and Public Health], IT | ||
Line 55: | Line 55: | ||
::::* Prof. Dr. Felix Distelmaier - [https://www.uniklinik-duesseldorf.de/en/department-of-general-paediatrics Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University], DE | ::::* Prof. Dr. Felix Distelmaier - [https://www.uniklinik-duesseldorf.de/en/department-of-general-paediatrics Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University], DE | ||
::::* Dr. Nael Nadif Kasri - [https://www.radboudumc.nl/en/research/departments/human-genetics Radboud University Medical Centre, Department of Human Genetics], NL Â | ::::* Dr. Nael Nadif Kasri - [https://www.radboudumc.nl/en/research/departments/human-genetics Radboud University Medical Centre, Department of Human Genetics], NL Â | ||
::::* [[ | ::::* [[Cecatto Cristiane| Dr. Cristiane Cecatto]] - [https://www.oroboros.at/ Oroboros Instruments GmbH], AT | ||
::::* Dr. Valeria Tiranti -Â [https://www.istituto-besta.it/ Foundation IRCCS Neurological Institute C. Besta, Unit of Molecular Neurogenetics], IT | ::::* Dr. Valeria Tiranti -Â [https://www.istituto-besta.it/ Foundation IRCCS Neurological Institute C. Besta, Unit of Molecular Neurogenetics], IT | ||
::::* Dr. Dario Brunetti - [http://eng.biometra.unimi.it/ecm/home University of Milan, Department of Medical Biotechnology and Translational Medicine], IT | ::::* Dr. Dario Brunetti - [http://eng.biometra.unimi.it/ecm/home University of Milan, Department of Medical Biotechnology and Translational Medicine], IT | ||
Line 71: | Line 71: | ||
== Oroboros project involvement == | == Oroboros project involvement == | ||
:::: Oroboros is a collaborator on the project providing infrastructure and expertise required to conduct respirometric measurements for the project. | :::: Oroboros is a collaborator on the project providing infrastructure and expertise required to conduct respirometric measurements for the project. | ||
== Links == | |||
 | |||
'''News and articles ''' | |||
 | |||
:::: 2021-01-19 Press release: [https://www.itmp.fraunhofer.de/en/press/EJP-RD-CureMILS-TreatKCNQ.html Fraunhofer ITMP involved in two new European research consortia on research rare childhood diseases] | |||
 | |||
== Support == | == Support == | ||
The EJP RD initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575. EJP RD is coordinated by INSERM, France. | The EJP RD initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575. EJP RD is coordinated by INSERM, France. | ||
[[File:Flag yellow low.jpg|left|100px]] | [[File:Flag yellow low.jpg|left|100px]] |
Latest revision as of 15:30, 13 January 2023
CureMILS
"A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome (MILS)"
CureMILS: European Joint Programme on Rare Diseases - JTC2020
- EJP RD JTC 2020: "PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASESâ - Project EJPRD20-010
- Duration: 36 months
- Start: 2021-06-01
About CureMILS
- Mitochondrial DNA (mtDNA)-associated Leigh syndrome (MILS) is a severe early-onset brain disease affecting 1/100,000 newborns. MILS is typically caused by mtDNA mutations in the ATP-generating subunit MT-ATP6. There are no treatments available for MILS. In fact, drug discovery is particularly challenging for MILS. The limited access to patient neural tissue and the difficulty to manipulate mtDNA hinder the development of transgenic animal models and cellular models, which are needed for treatment discovery and development. Led by Prof. Dr. Alessandro Prigione of the Heinrich Heine University, the CureMILS project aims to employ a novel approach to enable drug discovery of MILS.
Aims
- The consortium will employ neural cells generated from MILS patients via cellular reprogramming to carry out a large-scale screening using marketed drugs, thereby allowing the identification of therapeutic strategies.
- The proof-of-concept study demonstrated that this approach is feasible and relevant. The project proposes to extend this approach using a large high-quality library of repurposable compounds (more than 5,500). The consortium will validate hit compounds by combining mitochondrial profiling with multi-omics analysis using various reprogramming-derived neural models (neural progenitors, neurons, brain organoids, and blood-brain barrier cells) from different MILS patients.
Objectives
- The consortium will identify drugs suited for repositioning as interventions in MILS, laying the foundation for a multi-national clinical trial and a concrete path towards a cure for MILS.
- Moreover, we will establish a paradigmatic working pipeline for reprogramming-driven drug discovery and repositioning for rare neurological disorders.
Coordinator
Network
Consortium members
- Dr. Ole Pless - Fraunhofer IME, Department ScreeningPort, DE
- Prof. Dr. Frank Edenhofer - Institute for Molecular Biology, University of Innsbruck, AT
- Dr. Werner Koopman - Radboud University Medical Center, Biochemistry, NL
- Dr. Anu Suomalainen - University of Helsinki, Research Program of Stem Cells and Metabolism, FI
- Dr. PaweĆ Lisowski - Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Department of Molecular Biology, PL
- Dr. Emanuela Bottani - Verona University, Department of Diagnostics and Public Health, IT
- Dr. Antonio del Sol - Luxembourg Centre for Systems Biomedicine (LCSB) University of Luxembourg, LU
- Dr. Philip Yeske - International Mito Patients (IMP)
Collaborators
- Prof. Dr. Markus Schuelke - Charité University, Clinic for Pediatrics and Neurology, DE
- Prof. Dr. Felix Distelmaier - Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University, DE
- Dr. Nael Nadif Kasri - Radboud University Medical Centre, Department of Human Genetics, NL
- Dr. Cristiane Cecatto - Oroboros Instruments GmbH, AT
- Dr. Valeria Tiranti - Foundation IRCCS Neurological Institute C. Besta, Unit of Molecular Neurogenetics, IT
- Dr. Dario Brunetti - University of Milan, Department of Medical Biotechnology and Translational Medicine, IT
- Dr. David Meierhofer - Max Planck Institute for Molecular Genetics, DE
- Prof. Dr. Thomas Klopstock - Deutsches MITONET e.V., Friedrich-Baur-Institut, DE
Oroboros project involvement
- Oroboros is a collaborator on the project providing infrastructure and expertise required to conduct respirometric measurements for the project.
Links
News and articles
- 2021-01-19 Press release: Fraunhofer ITMP involved in two new European research consortia on research rare childhood diseases
Support
The EJP RD initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575. EJP RD is coordinated by INSERM, France.